Experimental cancer therapy targets tough tumors with radioactive precision

NCT ID NCT05130255

Terminated Disease control Sponsor: Y-mAbs Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested a two-step radioimmunotherapy combining GD2-SADA and 177Lu-DOTA in patients with recurrent or metastatic solid tumors, including small cell lung cancer, high-risk neuroblastoma, sarcoma, and melanoma. The goal was to assess safety and find the right dose. The study was terminated early after enrolling 23 participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GD2-SADA and 177Lu-DOTA (two-step radioimmunotherapy)
What this could lead to: If successful, this could point toward a new treatment option for patients with hard-to-treat cancers that express GD2.
What could go wrong: This was an early, terminated Phase 1 trial with only 23 participants, so results are limited. The approach may not prove effective or safe in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH-RISK NEUROBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma neuroblastoma sarcoma small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIGH-RISK NEUROBLASTOMA MALIGNANT MELANOMA SARCOMA SCLC

Contacts and locations

Locations

Case Western Reserve University, Cleveland

Cleveland, Ohio, 44106, United States
City of Hope National Medical Center

Duarte, California, 91010, United States
Corewell Health-BAMF Health

Grand Rapids, Michigan, 49503, United States
HonorHealth

Scottsdale, Arizona, 85258, United States
Memorial Sloan- Kettering Cancer Center

New York, New York, 10065, United States
UPMC Hillman Cancer Center

Pittsburgh, Pennsylvania, 15260, United States
University of Chicago

Chicago, Illinois, 60637, United States
University of Wisconsin-Madison

Madison, Wisconsin, 53705, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.